Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

LYRA: Maintenance therapy with daratumumab improves depth of response and...

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )

KRd consolidation in MM patients with a positive PET-CT after standard first...

Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with...

Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center...

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell...

Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory...

Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center

$Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )$

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?

Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )

Predicting early relapse in transplant-eligible MM patients using baseline...

Dr Francesca Gay - University of Torino, Torino, Italy

Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity ( Dr Francesca Gay - University of Torino, Torino, Italy )

Using multiparameter flow cytometry and next generation sequencing to evaluate...

Dr Francesca Gay - University of Torino, Torino, Italy

Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial ( Dr Francesca Gay - University of Torino, Torino, Italy )

More from ecancer